我們很高興地向大家介紹Medix Biochemica新任CEO：Steve Ferguson，他已于2020年1月1日就任。
在加入Medix Biochemica之前，Steve擔(dān)任Thermo Fisher免疫診斷部門的歐洲商業(yè)運(yùn)營(yíng)副總裁；再之前，他在制藥行業(yè)擔(dān)任過各種管理職務(wù)。
在體外診斷行業(yè)的全球發(fā)展規(guī)劃是Medix Biochemica的重中之重，對(duì)于Steve能夠加入Medix的大家庭，并幫助Medix和Medix的合作伙伴攜手并進(jìn)，共續(xù)輝煌，我們感到無比高興。
以下是Steve的訪談簡(jiǎn)報(bào)：
問題：請(qǐng)用自己的話描述一下您的目標(biāo)是什么？
Question: In your own words, what do you do?
回答：我加入Medix是為了成就一個(gè)成功的企業(yè)，實(shí)現(xiàn)董事會(huì)的宏圖，并讓Medix Biochemica集團(tuán)成為合作伙伴心目中的行業(yè)領(lǐng)導(dǎo)者。我希望實(shí)現(xiàn)公司愿景：成為IVD行業(yè)關(guān)鍵原料的首選供應(yīng)商。作為首席執(zhí)行官，我的職責(zé)是確保我們有明確的規(guī)劃，并保證我們所有的員工、資產(chǎn)配置和投資活動(dòng)都以實(shí)現(xiàn)這個(gè)愿景為共同目標(biāo)。
Answer: I joined Medix to build on a successful business, to fulfill the ambition of the Board and to establish Medix Biochemica Group as the clear leader in the eyes of our customers. I want to deliver on our ambition to be the number one supplier of critical raw materials to the IVD industry. As CEO, my role is to ensure we have a clear plan in place, and all our people, assets and investments are aligned to deliver that ambition.
問題：您認(rèn)為是什么讓Medix Biochemica在行業(yè)中脫穎而出?
Question: What would you say makes Medix Biochemica stand out among other companies?
回答：高質(zhì)量的產(chǎn)品，專業(yè)的員工，以及大規(guī)模生產(chǎn)的能力，無論是歐洲、美國(guó)還是中國(guó)，只要客戶有需要。新的IVD法規(guī)意味著我們服務(wù)客戶和加強(qiáng)供應(yīng)鏈的愿望和行動(dòng)完全符合IVD行業(yè)的需求。對(duì)我們的客戶來說，IVD法規(guī)意味著更高的要求，且安全可靠的原料供應(yīng)商極為重要。我們這方面的優(yōu)勢(shì)將有力地幫助合作伙伴完成適應(yīng)新法規(guī)的轉(zhuǎn)變。
Answer: The quality of our products, the expertise of our people, and our ability to scale manufacturing in the three regions where our customers need us: Europe, the US, and China. New regulations mean our desire to serve our customers and consolidate the supply chain is perfectly aligned to the needs of the IVD industry. IVD regulation is a burden to our customers and it means they must have secure and reliable raw material suppliers. We are in a great position to help our customers as they are going through change themselves.
問題：您認(rèn)為Medix Biochemica的前景如何?
Question: How does Medix Biochemica’s future look like?
回答：前景燦爛，節(jié)奏明快！通過卓越的商業(yè)運(yùn)營(yíng)、加速的研發(fā)產(chǎn)品線和并購(gòu)，我們將不斷擴(kuò)充提供給IVD合作伙伴的產(chǎn)品線，并成為最重要的供應(yīng)商。2019年對(duì)Lee Biosolutions的收購(gòu)，是我們擴(kuò)充客戶服務(wù)的第一步。這是眾多審慎評(píng)估的并購(gòu)計(jì)劃中的第一個(gè)，我們將在2020年加快腳步。Medix集團(tuán)正在不斷發(fā)展，Medix大家庭也在不斷壯大。對(duì)于每個(gè)Medix的成員來說，這將會(huì)是一個(gè)充滿樂趣的旅程！
Question: Bright and fast-paced! Through commercial excellence, pipeline acceleration and inorganic acquisition, we will broaden our offering to IVD customers and become the most relevant supplier to them. The acquisition of Lee Bio Solutions in 2019 sees our first step in widening our customer offering. That is the first of many carefully planned acquisitions, and we will intensify our actions here in 2020. The Medix group is expanding and the Medix family is growing. This should be a fun journey for everyone at Medix!
如您有任何問題，請(qǐng)隨時(shí)聯(lián)系我們。
Medix中國(guó)：
上海墨迪斯醫(yī)療技術(shù)有限公司
上海市浦東周浦天雄路588號(hào)21幢402室
電話：+86 21 6811 9180, 6811 9181, 6811 9105
傳真：+86 21 6811 9125
郵箱：medixchina@medixbiochemica.com
中文網(wǎng)站：cnmedixbiochemica.com